Population-based analysis of CHEK2 pathogenic variants and their functional role in breast cancer development

  • N. Khudoyberdieva Alfraganus University
  • I. Amanturdiev National University of Uzbekistan
  • G. Boqieva Alfraganus University
  • N. Arabova Alfraganus University
  • S. Shakarboeva Jizzakh State Pedagogical University
  • S. Ziyamukhamedova Uzbekistan State University of Physical Education and Sport
  • M. Umorov Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology
  • N. Avezov Institute of Biophysics and Biochemistry at the National University of Uzbekistan
  • K. Akhmedov Tashkent State Agrarian University
  • K. Burieva Turon University
DOI: https://doi.org/10.15421/0226016
Keywords: CHEK2 gene, IVS2 1G>A polymorphism, Ile157Thr polymorphism, breast cancer, DNA damage response, genetic susceptibility, Uzbek population.

Abstract

CHEK2 is an essential tumor suppressor gene involved in DNA damage response and cell cycle regulation, and its germline variants are known to increase breast cancer suscept i bility. However, evidence regarding the clinical and molecular relevance of CHEK2 variants in Central Asian populations remains limited. This study aimed to assess the distribution and clinicopathological significance of the CHEK2 IVS2+1G>A and Ile157Thr polymorphisms in Uzbek women with breast cancer, with emphasis on molecular subtypes, immunohistochemical markers, and menopausal status. The study included 200 breast ca n cer patients and 100 conditionally healthy controls. CHEK2 polymorphisms were identified using PCR-based genotyping. Associations with clinicopathological features and immunohistochemical markers (ER, PR, HER2/ neu , Ki -67) were evaluated using odds ratios, relative risk estimates, χ² test, and Fisher’s exact test. The IVS2+1G>A variant was significantly associated with hormone receptor–positive tumors, predominantly luminal subtypes, and was more frequently observed in postmenopausal patients. In contrast, the Ile157Thr polymorphism showed a wider age distribution and was linked to a heterogeneous molecular profile, including highly proliferative and triple-negative breast cancer subtypes. Distinct patterns of hormone receptor expression and Ki-67 levels suggested variant-specific biological behavior. These findings demonstrate that CHEK2 polymorphisms differentially influence breast cancer risk and phenotype in a menopause-dependent manner. The results highlight the importance of population-specific genetic profiling and support the potential utility of CHEK2 variants in personalized risk stratification for breast cancer in Uzbek wo m en.

References

Agaoglu, N. B., Ng, O. H., Unal, B., Dogan, O. A., Amanvermez, U., Yildiz, J., Doganay, L., Ghazani, A. A., & Rana, H. Q. (2022). Concurrent pathogenic variants of BRCA1, MUTYH and CHEK2 in a hereditary cancer family. Cancer Genetics, 268–269, 128–136.

Akbar, F., Siddiqui, Z., Waheed, M. T., Ehsan, L., Ali, S. I., Wiquar, H., Valimohammed, A. T., Khan, S., Vohra, L., Zeeshan, S., Rashid, Y., Moosajee, M., Jabbar, A. A., Zahir, M. N., Zahid, N., Soomro, R., Ullah, N. N., Ahmad, I., Haider, G., … Kirmani, S. (2022). Spectrum of germline pathogenic variants using a targeted next generation sequencing panel and genotype-phenotype correlations in patients with suspected hereditary breast cancer at an academic medical centre in Pakistan. Hereditary Cancer in Clinical Practice, 20, 24.

Akhtam, R., Nuraliyevna, S. N., Kadham, M. J., Mirzakhamitovna, K. S., Tursunaliyevna, R. M., Shakhnoz, K., Shakhzod, T., Otabek, B., Baxtiyorovich, M. I., Shakhboskhanovna, A. F., Zulxumorxon, B., Isroilovna, I. M., & Khodji-Akbarovna, N. R. (2025). Biomarkers in liver regeneration. Clinica Chimica Acta, 576, 120413.

Angeli, D., Salvi, S., & Tedaldi, G. (2020). Genetic predisposition to breast and ovarian cancers: How many and which genes to test? International Journal of Molecular Sciences, 21(3), 1128.

Anoushirvani, A., Ahmadi, A., Arjomandzadegan, M., Aghabozorgi, R., Jafari, M., & Mehrabbeygi, F. (2019). Detection of CHEK2 Ile157Thr mutation in cancer patients by using allele specific PCR. Journal of Research in Medical and Dental Science, 7(1), 206–210.

Ansari, N., Shahrabi, S., Khosravi, A., Shirzad, R., & Rezaeean, H. (2019). Prognostic significance of CHEK2 mutation in progression of breast cancer. Laboratory Medicine, 50(3), e36–e41.

Apostolou, P., & Papasotiriou, I. (2017). Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer: Targets and Therapy, 9, 331–335.

Apostolou, P., Fostira, F., Mollaki, V., Delimitsou, A., Vlassi, M., Pentheroudakis, G., Faliakou, E., Kollia, P., Fountzilas, G., Yannoukakos, D., & Konstantopoulou, I. (2018). Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. Journal of Human Genetics, 63(8), 877–886.

Baynes, C., Healey, C. S., Pooley, K. A., Scollen, S., Luben, R. N., Thompson, D. J., Pharoah, P. D., Easton, D. F., Ponder, B. A., & Dunning, A. M. (2007). Common variants in ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Research, 9(2), R27.

Bell, D. W., Kim, S. H., Godwin, A. K., Schiripo, T. A., Harris, P. L., Haserlat, S. M., Wahrer, D. C. R., Haiman, C. A., Daly, M. B., Niendorf, K. B., Smith, M. R., Sgroi, D. C., Garber, J. E., Olopade, O. I., Marchand, L. L., Henderson, B. E., Altshuler, D., Haber, D. A., & Freedman, M. L. (2007). Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. International Journal of Cancer, 121(12), 2661–2667.

Blanter, J., Zimmerman, B., Tharakan, S., Ru, M., Cascetta, K., & Tiersten, A. (2020). BRCA mutation association with recurrence score and discordance in a large oncotype database. Oncology, 98(4), 248–251.

Bono, M., Fanale, D., Incorvaia, L., Cancelliere, D., Fiorino, A., Calò, V., Dimino, A., Filorizzo, C., Corsini, L. R., Brando, C., Madonia, G., Cucinella, A., Scalia, R., Barraco, N., Guadagni, F., Pedone, E., Badalamenti, G., Russo, A., & Bazan, V. (2021). Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: Looking over the hedge. ESMO Open, 6(4), 100235.

Boonen, R. A. C. M., Vreeswijk, M. P. G., & van Attikum, H. (2022). CHEK2 variants: Linking functional impact to cancer risk. Trends in Cancer, 8(9), 759–770.

Boonen, R. A. C. M., Wiegant, W. W., Celosse, N., Vroling, B., Heijl, S., Kote-Jarai, Z., Mijuskovic, M., Cristea, S., Solleveld-Westerink, N., van Wezel, T., Beerenwinkel, N., Eeles, R., Devilee, P., Vreeswijk, M. P. G., Marra, G., & van Attikum, H. (2023). Data from functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk. American Association for Cancer Research. Collection.

Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., Złowocka, E., Lenner, M., Grabowska, E., Nej, K., Castaneda, J., Mędrek, K., Szymańska, A., Szymańska, J., Kurzawski, G., … Lubiński, J. (2004a). CHEK2 is a multiorgan cancer susceptibility gene. The American Journal of Human Genetics, 75(6), 1131–1135.

Darbeheshti, F., Kadkhoda, S., Keshavarz-Fathi, M., Razi, S., Bahramy, A., Mansoori, Y., & Rezaei, N. (2022). Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness. BMC Cancer, 22, 668.

Delimitsou, A., Fostira, F., Kalfakakou, D., Apostolou, P., Konstantopoulou, I., Kroupis, C., Papavassiliou, A. G., Kleibl, Z., Stratikos, E., Voutsinas, G. E., & Yannoukakos, D. (2019). Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system. Human Mutation, 40(5), 631–648.

Han, F., Guo, C., & Liu, L. (2013). The effect of CHEK2 variant I157T on cancer susceptibility: Evidence from a meta-analysis. DNA and Cell Biology, 32(6), 329–335.

Hauke, J., Horvath, J., Groß, E., Gehrig, A., Honisch, E., Hackmann, K., Schmidt, G., Arnold, N., Faust, U., Sutter, C., Hentschel, J., Wang-Gohrke, S., Smogavec, M., Weber, B. H. F., Weber-Lassalle, N., Weber-Lassalle, K., Borde, J., Ernst, C., Altmüller, J., … Hahnen, E. (2018). Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Medicine, 7(4), 1349–1358.

Hawsawi, Y. M., Shams, A., Theyab, A., Abdali, W. A., Hussien, N. A., Alatwi, H. E., Alzahrani, O. R., Oyouni, A. A. A., Babalghith, A. O., & Alreshidi, M. (2022). BARD1 mystery: Tumor suppressors are cancer susceptibility genes. BMC Cancer, 22, 599.

Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., Gao, C., Lilyquist, J., Yadav, S., Boddicker, N. J., Samara, R., Klebba, J., Ambrosone, C. B., Anton-Culver, H., Auer, P., Bandera, E. V., Bernstein, L., Bertrand, K. A., Burnside, E. S., … Couch, F. J. (2021). A population-based study of genes previously implicated in breast cancer. New England Journal of Medicine, 384(5), 428–439.

Hu, C., Zhang, S., Gao, X., Gao, X., Xu, X., Lv, Y., Zhang, Y., Zhu, Z., Zhang, C., Li, Q., Wong, J., Cui, Y., Zhang, W., Ma, L., & Wang, C. (2012). Roles of Kruppel-associated box (KRAB)-associated Co-repressor KAP1 Ser-473 phosphorylation in DNA damage response. Journal of Biological Chemistry, 287(23), 18937–18952.

Kiani, M. N., Khaliq, H., Abubakar, M., Rafique, M., Jalilov, F., Ashraf, G. A., Ayari-Akkari, A., & Akremi, A. (2025). Advancing the potential of nanoparticles for cancer detection and precision therapeutics. Medical Oncology, 42, 239.

Li, J.-Y., Jing, R., Wei, H., Wang, M., Xiaowei, Q., Liu, H., Jian, L., Ou, J.-H., Jiang, W.-H., Tian, F.-G., Sheng, Y., Li, H.-Y., Xu, H., Zhang, R.-S., Guan, A.-H., Liu, K., Jiang, H.-C., Ren, Y., He, J.-J., … Jiang, J. (2019). Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. International Journal of Cancer, 144(2), 281–289.

Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020). Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer. Frontiers in Pharmacology, 11, 580251.

Liu, C., Wang, Y., Wang, Q.-S., & Wang, Y.-J. (2012). The CHEK2 I157T variant and breast cancer susceptibility: A systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention, 13(4), 1355–1360.

Mandelker, D., Kumar, R., Pei, X., Selenica, P., Setton, J., Arunachalam, S., Ceyhan-Birso, O., Brown, D. N., Norton, L., Robson, M. E., Wen, H. Y., Powell, S., Riaz, N., Weigelt, B., & Reis-Filho, J. S. (2019). The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers. JNCI Cancer Spectrum, 3(2), pkz027.

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., … Skibelund, A. K. (2021). Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(48), 4901.

Nevanlinna, H., & Bartek, J. (2006). The CHEK2 gene and inherited breast cancer susceptibility. Oncogene, 25(43), 5912–5919.

Onarheim, K. H., Iversen, J. H., & Bloom, D. E. (2016). Economic benefits of investing in women’s health: A systematic review. PLoS One, 11(3), e0150120.

Panegyres, K. (2024). The story of how cancer got its name. Cancer, 130(20), 3665–3667.

Staples, M., Fang, N.-X., Graham, R. M., Smith, H. V., & Jennison, A. V. (2017). Evaluation of SHIGA TOXIN QUIK CHEK and ImmunoCard STAT! EHEC as screening tools for detection of Shiga toxin in fecal specimens. Diagnostic Microbiology and Infectious Disease, 87(2), 167–169.

Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., & Kleibl, Z. (2020). CHEK2 germline variants in cancer predisposition: Stalemate rather than checkmate. Cells, 9(12), 2675.

Tahir, D.-E.-S., Rehman, M. S., & Ul Rehman, M. S. (2020). An overview of cancer genetics with focus on involvement of BRCA1/2 genes in breast carcinomas. Journal of the Pakistan Medical Association, 70(7), 1240–1247.

Tian, J.-M., Ran, B., Zhang, C.-L., Yan, D.-M., & Li, X.-H. (2018). Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression. Brazilian Journal of Medical and Biological Research, 51(3), e5612.

Tischkowitz, M., Balmaña, J., Foulkes, W. D., James, P., Ngeow, J., Schmutzler, R., Voian, N., Wick, M. J., Stewart, D. R., & Pal, T. (2021). Management of individuals with germline variants in PALB2. Genetics in Medicine, 23(8), 1416–1423.

Topaktaş, M., Akkız, H., Bekar, A., & Akgöllü, E. (2012). CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from the Turkish population. Cancer Epidemiology, 36(5), e346–e350.

Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., … Zakalik, D. (2020). Management of hereditary breast cancer: ASCO, ASTRO, and SSO guideline. Journal of Clinical Oncology, 38(18), 2080–2106.

Wagener, R., Walter, C., Auer, F., Alzoubi, D., Hauer, J., Fischer, U., … Brozou, T. (2023). The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients. International Journal of Cancer, 152(7), 1285–1297.

Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A review. Journal of the American Medical Association, 321(3), 288–300.

Wei, G., Teng, M., Rosa, M., & Wang, X. (2022). Unique ER/PR expression pattern in breast cancers with CHEK2 mutation. Breast Cancer Research, 24(1), 11.

Weidner, A. E., Liggin, M. E., Zuniga, B. I., Tezak, A. L., Wiesner, G. L., & Pal, T. (2020). Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers. Cancer, 126(8), 1822–1830.

Willoughby, A., Andreassen, P. R., & Toland, A. E. (2019). Genetic testing to guide risk-stratified screens for breast cancer. Journal of Personalized Medicine, 9(1), 15.

Wu, J., Mamidi, T. K. K., Zhang, L., & Hicks, C. (2019). Integrating germline and somatic mutation information for biomarker discovery in TNBC. International Journal of Environmental Research and Public Health, 16(6), 1055.

Wu, X., Webster, S. R., & Chen, J. (2001). Characterization of tumor-associated Chk2 mutations. Journal of Biological Chemistry, 276(4), 2971–2974.

Yu, P., Zhu, X., Zhu, J.-L., Han, Y.-B., Zhang, H., Zhou, X., … Kong, L.-Y. (2021). The Chk2–PKM2 axis promotes metabolic control of vasculogenic mimicry in TNBC. Oncogene, 40(34), 5262–5274.

Zeng, Y., Li, J., Guo, W., Luo, W., Liu, X., He, R., … Luo, D. (2021). AKR1B10 protects against UVC-induced DNA damage in breast cancer cells. Acta Biochimica et Biophysica Sinica, 53(6), 729–738.

Zhang, M., Qu, J., Gao, Z., Qi, Q., Yin, H., Zhu, L., … Huang, X. (2021). Timosaponin AIII induces G2/M arrest and apoptosis in breast cancer via ATM/Chk2 signaling. Frontiers in Pharmacology, 11, 601468.

Zhao, K. L., Liu, Y., Scherpelz, K. P., Kao, D. S., & Friedrich, J. B. (2021). Occult primary breast cancer presenting with brachial plexopathy: A case report. SAGE Open Medical Case Reports, 9, 2050313X20985646.

Złowocka-Perłowska, E., Narod, S. A., & Cybulski, C. (2019). CHEK2 alleles predispose to renal cancer in Poland. JAMA Oncology, 5(4), 576.

Zografos, E., Korakiti, A.-M., Andrikopoulou, A., Rellias, I., Dimitrakakis, C., Marinopoulos, S., … Zagouri, F. (2021). Germline mutations in pregnancy-associated breast cancer patients. BMC Cancer, 21(1), 622.

Published
2026-01-29
How to Cite
Khudoyberdieva, N., Amanturdiev, I., Boqieva, G., Arabova, N., Shakarboeva, S., Ziyamukhamedova, S., Umorov, M., Avezov, N., Akhmedov, K., & Burieva, K. (2026). Population-based analysis of CHEK2 pathogenic variants and their functional role in breast cancer development. Regulatory Mechanisms in Biosystems, 17(1), e26016. https://doi.org/10.15421/0226016
Issue
Vol 17 No 1 (2026): Regulatory Mechanisms in Biosystems
Section
Статті

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Most read articles by the same author(s)